Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Poseida Therapeutics (PSTX)
NASDAQ:PSTX
Poseida Therapeutics (PSTX) Stock Price & Analysis
269 Followers
PSTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.54 - $4.27
Previous Close$2.43
Volume1.02M
Average Volume (3M)738.94K
Market Cap
$200.70M
Enterprise Value$107.69M
Total Cash (Recent Filing)$212.20M
Total Debt (Recent Filing)$85.42M
Price to Earnings (P/E)-1.8
Beta1.13
Next Earnings
May 07, 2024EPS Estimate
-$0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding96,489,127
10 Day Avg. Volume431,148
30 Day Avg. Volume738,942
Standard Deviation0.20
R-Squared0.00802
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.68
Price to Sales (P/S)10.54
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.66
Enterprise Value/Gross Profit1.66
Enterprise Value/Ebitda-1.24
Forecast
1Y Price Target
$14.00Price Target Upside573.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Poseida Therapeutics News
PremiumCompany Announcements
Poseida Therapeutics Shares Genetic Medicine R&D Insights
PremiumCompany Announcements
Poseida Therapeutics Unveils Cancer Research Breakthroughs at AACR
Ownership Overview
39.84% Insiders
16.01% Mutual Funds
6.91% Other Institutional Investors
37.25% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PSTX FAQ
What was Poseida Therapeutics’s price range in the past 12 months?
Poseida Therapeutics lowest stock price was $1.54 and its highest was $4.27 in the past 12 months.
What is Poseida Therapeutics’s market cap?
Currently, no data Available
When is Poseida Therapeutics’s upcoming earnings report date?
Poseida Therapeutics’s upcoming earnings report date is May 07, 2024 which is in 19 days.
How were Poseida Therapeutics’s earnings last quarter?
Poseida Therapeutics released its earnings results on Mar 07, 2024. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.386 by $0.116.
Is Poseida Therapeutics overvalued?
According to Wall Street analysts Poseida Therapeutics’s price is currently Undervalued.
Does Poseida Therapeutics pay dividends?
Poseida Therapeutics does not currently pay dividends.
What is Poseida Therapeutics’s EPS estimate?
Poseida Therapeutics’s EPS estimate is -$0.42.
How many shares outstanding does Poseida Therapeutics have?
Poseida Therapeutics has 96,489,130 shares outstanding.
What happened to Poseida Therapeutics’s price movement after its last earnings report?
Poseida Therapeutics reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.386. Following the earnings report the stock price went up 18.659%.
Which hedge fund is a major shareholder of Poseida Therapeutics?
Among the largest hedge funds holding Poseida Therapeutics’s share is Aisling Capital Management LP. It holds Poseida Therapeutics’s shares valued at 4M.
---
Poseida Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.00 (573.08% Upside)
$14.00 (573.08% Upside)
Blogger Sentiment
Bullish
PSTX Sentiment 75%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 2.7%
Last 30 Days ▲ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.00%
12-Months-Change
Fundamentals
Return on Equity
-84.75%
Trailing 12-Months
Asset Growth
-24.14%
Trailing 12-Months
Company Description
Poseida Therapeutics
Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumors.
---
PSTX Stock 12 Months Forecast
Average Price Target
$14.00
▲(573.08% Upside)
Technical Analysis
Best Analysts Covering PSTX
1 Year
1 Year Success Rate
9/18 ratings generated profit
1 Year Average Return
+0.71%
assigned a buy rating 7 days ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +0.71% per trade.
---